However, the activation of the RAS pathway driven by mechanisms independent of BCR::ABL1 signalling, such as mutations in intermediates of the RAS pathway, can lead to TKI resistance in CML [58,59]. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.